Threat to Advair from cheap generics greets GSK's new CEO
Wed, Feb 08, 2017 - 5:50 AM
GlaxoSmithKline's incoming CEO Emma Walmsley will be taking over the reins at a time when the company's inhaled lung drug Advair faces threat from cheap generics.
PHOTOS: BLOOMBERG, REUTERS
EMMA Walmsley, GlaxoSmithKline's incoming CEO, will take over Britain's biggest drugmaker at a challenging time but the 47-year-old also inherits the flexibility to do deals and make key choices on new drugs.
Just four days before she moves into the top job on April 1, US...